Synthesis of 4‐(Carbonyloxyphenyl)‐1, 4‐Dihydropyridines as Potential Antihypertensive Agents. Issue 1 (28th December 2012)

• Record Type: Journal Article
• Authors: Bansal, Ranju; Narang, Gaurav; Calle, Carmen; Carron, Rosalia; Pemberton, Karen; Harvey, Alan L.
• Is Part Of: Drug development research. Volume 74:Issue 1(2013)
• Page Start: 50
• Page End: 61
• Publication Date: 2012-12-28
• Subjects: Drug development -- Periodicals; Drugs -- Research -- Periodicals; 615.19
• DOI: 10.1002/ddr.21056
• Languages: English
• ISSNs: 0272-4391

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p> <table-wrap position="anchor" orientation="portrait"> <label> <x xml:space="preserve">Table </x> </label> <table border="1"> <colgroup span="1"> <col align="left" span="1" /> </colgroup> <tbody> <tr> <td align="left" rowspan="1" colspan="1">Preclinical Research</td> </tr> </tbody> </table> </table-wrap> </p> <p>A series of novel symmetric and asymmetric 4‐(carbonyloxyphenyl)‐1, 4‐dihydropyridines (DHPs) was synthesized and evaluated for calcium channel blocking, vasodilatory and antihypertensive properties. Some of these new DHPs displayed potent calcium channel blocking and good vasodilatory activities. Heart rate remained relatively constant in comparison with blood pressure changes in the case of these newly synthesized compounds, thereby decreasing the probability of reflex tachycardia, a major side effect of nifedipine. The most potent compound, ethyl methyl 4‐(3‐isopropylcarbonyloxyphenyl)‐2, 6‐dimethyl‐1, 4‐dihydropyridine‐3, 5‐dicarboxylate <bold>(14c)</bold> exhibited antihypertensive activity comparable with the standard drug—nifedipine.</p> </abstract>